US 12,140,599 B2
Mass spectrometric determination of testosterone in multiplexed patient samples
Mildred M. Goldman, Laguna Niguel, CA (US); Scott Goldman, Laguna Niguel, CA (US); Julia Colletti, Mission Viejo, CA (US); and Nigel Clarke, Vista, CA (US)
Assigned to Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed by Quest Diagnostics Investments LLC, Secaucus, NJ (US)
Filed on May 4, 2023, as Appl. No. 18/143,226.
Application 18/143,226 is a continuation of application No. 16/355,552, filed on Mar. 15, 2019, granted, now 11,674,969.
Claims priority of provisional application 62/644,351, filed on Mar. 16, 2018.
Prior Publication US 2023/0273226 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/74 (2006.01); G01N 30/50 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/743 (2013.01) [G01N 30/50 (2013.01); G01N 33/6848 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method for determining the amount of testosterone in each of at least two human samples by a single tandem mass spectrometry assay, the method comprising:
i) subjecting each of at least two human samples to a different derivatizing agent to generate a differently derivatized testosterone in each of the at least two human samples, wherein the derivatization agents comprise methoxyamine chloride and hydroxylamine chloride;
ii) combining the at least two human samples to form a multiplex sample;
iii) purifying the sample by liquid chromatography; and
iv) quantifying the amount of testosterone in each sample by tandem mass spectrometry.